Nurix Therapeutics has named Arati V. Rao, M.D., as its new chief medical officer to oversee the clinical development of its pipeline, including the registrational program for bexobrutideg.
The company announced the appointment of Arati V. Rao, M.D., as chief medical officer on November 11, 2026. She brings more than 20 years of oncology and clinical development experience, including leadership of the registrational program for bexobrutideg with Roche. This is a routine senior management hire with no quantified financial effect on the outlook, so the price impact should be limited and direction uncertain.
Nurix Therapeutics announced the appointment of Arati V. Rao, M.D., as chief medical officer on November 11, 2026. Dr. Rao, formerly a vice president at Pfizer, brings over 20 years of experience in hematology-oncology and clinical development to lead the company's registrational program for bexobrutideg, which is being co-developed with Roche.
It is a routine leadership announcement without new financial or clinical data, so any price impact is likely minimal.
Arati V. Rao, M.D., joins from Pfizer with over 20 years of experience in hematology-oncology and clinical development. She will lead Nurix's clinical development organization, including the registrational program for bexobrutideg with Roche.